Patricia Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc. (NASDAQ: ), recently sold shares in the company. According to a filing with the Securities and Exchange Commission, Hirano sold a total of 3,030 shares of common stock between January 2 and January 3, 2025. approximately $138,709. The transaction came as the $2 billion market cap company was trading near $46 per share, with analysts setting price targets between $67 and $93. According to InvestingPro analysis, the stock currently appears to be overvalued relative to its Fair Value.

The sale was made to cover withholding tax obligations related to the vesting of restricted stock units (RSUs). Following these transactions, Hirano retained ownership of 105,902 shares of Soleno Therapeutics. InvestingPro The data reveals that the company maintains a strong financial health score of 2.22 (FAIR), with a key strength being that it has more cash than debt on its balance sheet. Subscribers can access 6 additional ProTips and a comprehensive Pro Research Report for a deeper understanding of SLNO’s financial position.

In other recent news, Soleno Therapeutics has been the subject of significant developments. Stifel named Soleno Therapeutics as one of its top biotech picks for 2025, citing future catalysts that could push the company’s value higher. The company also noted that Soleno Therapeutics is awaiting a regulatory decision, which could open up new opportunities in rare disease markets. Analysts from Baird, HC Wainwright, Oppenheimer, and Laidlaw remain optimistic about Soleno’s product, DCCR, for Prader-Willi syndrome, which plans to start generating revenue in mid-2025.

Other recent developments include changes to Soleno’s Board of Directors with the appointment of Matthew Pauls as the new Lead Independent (LON:) Director and the addition of Dawn Carter Bir. The company also entered into an agreement with Jefferies LLC to potentially sell up to $150 million of its common stock and grant performance-based restricted stock units to its employees.

The US Food and Drug Administration (FDA) has extended the review period for Soleno’s New Drug Application (NDA) for the DCCR, with a new target date of action set for March 27, 2025. Despite the delay At the time of review, analysts from various companies maintained a positive outlook on Soleno, with price targets ranging from $67 to $93.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.